Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Grifols S.A.

(NASDAQ: GRFS)
Add to Portfolio
-0.33 (-1.40%)
as of Jan 21, 2020

Last 23.31
Change -0.33 (-1.40%)
Open 23.32
Prev. Close 23.64
Today's Range
23.20
23.45
52wk Range
17.57
24.82
Volume 822,813
Avg Volume 853,880
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
GRFS -1.40% +7.82% +20.40%
DJIA -0.52% +6.20% +18.17%
S&P 500 -0.27% +7.93% +24.34%

Key Statistics

Annual EPS 0.90
Dividend Yield 1.44%
P/E Ratio 21.30
Market Capitalization, $K 16,253,680
Weighted Alpha +23.60
Standard Deviation -1.19
Profit Margin N/A
Beta 1.05

Growth Rates

YTD +0.09%
1-Year +22.11%
3-Year +40.13%
5-Year +39.39%

Opinion

Sell Hold Buy

Recent Headlines

Grifols launches XEMBIFY® (immune globulin

PR Newswire via COMTEX - Thu Dec 12, 09:24AM EST
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the (full story)
GRF: 7.81 (+0.03), GRFS: 23.31 (-0.33)

Grifols presents its latest Alzheimer's clinical trial

PR Newswire Europe via COMTEX - Fri Dec 06, 03:52PM EST
Neuroimaging shows AMBAR clinical trial's positive effects in patients with mild-to-moderate Alzheimer's disease(full story)
GRFS: 23.31 (-0.33), GRF: 7.81 (+0.03)

Grifols Streamlines Hospital Pharmacy Operations With

PR Newswire via COMTEX - Thu Dec 05, 10:26AM EST
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced the launch of its late(full story)
GRF.VN: 0.000 (unch), GRF: 7.81 (+0.03), GRFS: 23.31 (-0.33)

Grifols to present latest Alzheimer's clinical trial

PR Newswire Europe via COMTEX - Mon Dec 02, 09:46AM EST
Grifols , a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial at the Cli(full story)
GRFS: 23.31 (-0.33), GRF: 7.81 (+0.03)